Adoptive T Cell Immunotherapy For Cancer

Perica, Karlo; Varela, Juan Carlos; Oelke, Mathias; Schneck, Jonathan P.

doi:10.5041/rmmj.10179

Cited by 181 publications

(129 citation statements)

References 55 publications

Supporting

Mentioning

129

Contrasting

Order By: Relevance

“…Taken together, these findings indicate that combined treatment induces enhanced T-cell proliferation and activity. T cells have the ability to recognize and kill tumor cells (15,16). Moreover, combination therapy significantly inhibits tumor growth in comparison with either treatment alone, and thus potentiates antitumor efficacy as discussed above.…”

Section: Discussionmentioning

confidence: 99%

“…The interaction between T cells and dendritic cells results in activation and proliferation of T cells. Activated CD8 + T cells become cytotoxic T lymphocytes with the ability to recognize and kill tumor cells expressing the same antigen on the cell surface (15). Activated CD4 + T cells can provide help for CD8 + T cell activation by secreting interleukin-2 (16).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combination therapy with dendritic cell-based vaccine and anti-CD69 antibody enhances antitumor efficacy in renal cell carcinoma-bearing mice

et al. 2017

View full text Add to dashboard Cite

IntroductionRenal cell carcinoma accounts for 4% of all malignant tumors (1) and has an incidence of about 8-9 persons per 100,000 each year, which is increasing (2). There is no obvious symptom in the early stage of this cancer. As a result, approximately 25%-30% of patients exhibit tumor metastasis at first diagnosis and lose the opportunity for surgery (3). Although patients with primarily localized renal cell carcinoma can be successfully treated by partial or radical nephrectomy, one third of cases will subsequently develop metastases (4,5). Therapy of metastatic renal cell carcinoma is particularly difficult because of its poor response to radiotherapy or chemotherapy. Therefore, the prognosis for patients with metastatic renal cell carcinoma is poor, and the survival rate for 5 years is less than 10% (6). These lead to a rising demand for other treatment modalities.Prospective studies note spontaneous regression rates of up to 7% in patients with metastatic renal cell carcinoma (7,8). In addition, immunohistochemical studies of renal cell carcinoma often reveal tumor-infiltrating dendritic cells and T lymphocytes able to recognize and kill tumor cells (9). Therefore, renal cell carcinoma is considered an immunogenic tumor. These findings also lead to attempts to develop immunotherapeutic strategies using immunostimulatory cytokines such as interleukin-2 and interferon-α (10). It has been reported that treatment with interleukin-2 and interferon-α can induce antitumor activity in less than 20% of patients with metastatic renal cell carcinoma, but is associated with a high incidence Background/aim: Dendritic cell-based vaccine therapy for renal cell carcinoma is effective but requires improvement. Here we explored whether combination therapy with dendritic cell-based vaccine and anti-CD69 antibody can enhance antitumor efficacy in renal cell carcinoma-bearing mice.Materials and methods: Balb/c mice were challenged subcutaneously with murine renal cell carcinoma (Renca) cells. On day 3 after tumor cell inoculation, tumor-bearing mice either were left untreated or were treated with Renca tumor lysate-pulsed dendritic cells (i.e. dendritic cell-based vaccine), anti-CD69 antibody, or a combination of Renca tumor lysate-pulsed dendritic cells with anti-CD69 antibody. The mice were sacrificed on day 28. Tumor volume was measured for analysis of antitumor efficacy. Spleens were excised to evaluate antitumor immunological responses by measuring the proliferation and activation of T cells, which have the capacity to recognize and destroy tumor cells.Results: Combination treatment with Renca tumor lysate-pulsed dendritic cells and anti-CD69 antibody resulted in significant decreases in tumor volume and significant increases in T-cell proliferation and activity, compared with no treatment or either treatment alone. Conclusion:These findings indicate that anti-CD69 antibody can potentiate antitumor efficacy of dendritic cell-based vaccine. The augmented therapeutic efficacy conferred by the combination therapy may be as...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Combination therapy with dendritic cell-based vaccine and anti-CD69 antibody enhances antitumor efficacy in renal cell carcinoma-bearing mice

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The first clinical tests of adoptive transfer of CTLs have been permitted by improvement in CTL cell culture technology. This approach produces an immune response which is productive and vividly studied in patients suffering from melanoma (Perica et al, 2015). Patients suffering from refractory; metastatic melanoma can be treated in this way using CTLs that are infused following ex-vivo potentiation.…”

Section: Adoptive Ctl Therapymentioning

confidence: 99%

Cytotoxic T cells and Cancer Therapy

Chakraborty¹,

Latheef²,

Munjal³

et al. 2017

JEBAS

View full text Add to dashboard Cite

The cytotoxic T lymphocyte (CTL, Tc) is a type of T lymphocyte/ white blood cell involved in the host's cell-mediated immune response against cancerous cells, abnormal cells and cells infected with viruses. Signals from infected cells or cancer cells lead to the release of cytotoxins: perforin, granzymes, and granulysin by the TC cells. The activation of CTLs is mediated by the interaction of various costimulatory molecules as well as immune cells. Pre-eminent role of CTLs in combating cancer can be effectively applied for the active and passive immunotherapeutic approaches. Various recombinant cytokines viz., interleukins (IL)-2, 4, 7, 10, 12, 15; tumor necrosis factor (TNF) have been found to augment the production of CTL. CTLs can also be stimulated in antigen specific manner through tumor antigens which are the molecular derivatives over expressed in tumorcells due to differentiation, point mutations or viral origin. Designing and development of vaccines based on such immunogenic candidates can be executed and in majority of cases such antigens are targets for CTLs. Identification as chemotherapy and CTL-mediated killing. and validation of these CTL-specific antigens require

show abstract

“…The T-cells that show the greatest recognition of the patient's tumor cells in laboratory tests are selected, and large populations of these cells are grown in the laboratory. The cells are then activated by treatment with immune system signaling proteins called cytokines and infused into the patient's bloodstream [7].…”

Section: Adoptive Cell Transfer (Act)mentioning

confidence: 99%

Nanomedicine - the Future of Cancer Treatment: A Review

Sebastian¹

2017

JCPCR

View full text Add to dashboard Cite

Conventional cancer therapies are limited to surgery, radiation, and chemotherapy. Conventional treatments come with significant adverse effects. Modern cancer treatments focus on precise drug delivery to the cancer tissues and minimize adverse effects on healthy cells. Researchers have been working on an improved technique for delivering chemotherapeutic agents precisely at the molecular level in the tumor tissue. It has led to the use of nanotechnology in cancer treatment. Nanotechnology is the science and engineering of controlling matter, at the molecular scale, to create devices with novel chemical, physical and biological properties. Nanoscale objects are used themselves or as part of larger devices containing multiple nanoscale objects. Almost every field of Biosciences uses nanotechnology and all of which have an impact on biomedicine. It has the potential to change the current methods to diagnose and treat cancer. There has been real progress in translating nano-based cancer therapies and diagnostics into the clinic, and much more are in development. Nanoparticles are mainly used as nanocarriers to deliver the cytotoxic drugs to the tumor tissue. Use of nanoparticles is based on different concepts of pharmacology. Nanomedicine also is utilized to deliver multiple drugs at the cancer site at the same time for a better cytotoxic effect. CytImmune Sciences is a developing field of nanomedicine for targeted chemotherapy method. They selectively deliver the drug at the cancer site because of the increased permeability of the blood vessels at the tumor site. This article reviews various nanomedicine-based cancer therapeutics.

show abstract

Adoptive T Cell Immunotherapy For Cancer

Cited by 181 publications

References 55 publications

Combination therapy with dendritic cell-based vaccine and anti-CD69 antibody enhances antitumor efficacy in renal cell carcinoma-bearing mice

Combination therapy with dendritic cell-based vaccine and anti-CD69 antibody enhances antitumor efficacy in renal cell carcinoma-bearing mice

Cytotoxic T cells and Cancer Therapy

Nanomedicine - the Future of Cancer Treatment: A Review

Contact Info

Product

Resources

About